FDA Expands Use Of Approved Breast Cancer Drug
 

The U.S. Food and Drug Administration approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated. HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells...

More...